<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054725</url>
  </required_header>
  <id_info>
    <org_study_id>RMC-4630-03</org_study_id>
    <nct_id>NCT05054725</nct_id>
  </id_info>
  <brief_title>Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies</brief_title>
  <official_title>A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revolution Medicines, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Revolution Medicines, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in&#xD;
      subjects with KRASG12C mutant NSCLC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2 multicenter, open-label study evaluating the efficacy, safety,&#xD;
      tolerability, and pharmacokinetics (PK) of RMC-4630 in combination with sotorasib in subjects&#xD;
      with KRASG12C mutant NSCLC after failure of prior standard therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">January 19, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>ORR as assessed per RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Number of Participants with Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Number of Participants with Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Number of subjects with clinically significant changes in vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory test values</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Number of subjects with clinically significant changes in clinical laboratory test values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs Measurements</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Number of subjects with clinically significant changes in ECGs Measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of RMC-4630</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Trough Concentration of RMC-4630</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of sotorasib</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Trough Concentration of sotorasib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>DOR as assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>DCR as assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>PFS as assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Overall survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>RMC-4630 and sotorasib, Safety Run-in</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Safety Run-In:&#xD;
RMC-4630 and sotorasib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RMC-4630 and sotorasib, Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Expansion:&#xD;
RMC-4630 and sotorasib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RMC-4630</intervention_name>
    <description>RMC-4630 administered orally as a capsule</description>
    <arm_group_label>RMC-4630 and sotorasib, Expansion</arm_group_label>
    <arm_group_label>RMC-4630 and sotorasib, Safety Run-in</arm_group_label>
    <other_name>SAR442720</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotorasib</intervention_name>
    <description>Sotorasib administered orally as a tablet</description>
    <arm_group_label>RMC-4630 and sotorasib, Expansion</arm_group_label>
    <arm_group_label>RMC-4630 and sotorasib, Safety Run-in</arm_group_label>
    <other_name>AMG 510</other_name>
    <other_name>Lumakras</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be â‰¥18 years of age.&#xD;
&#xD;
          -  Subject must have pathologically documented, locally advanced or metastatic KRASG12C&#xD;
             NSCLC (not amenable to curative surgery) that has progressed on prior standard&#xD;
             therapies (no more than 3 prior lines of therapies are allowed)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Primary central nervous system (CNS) tumors&#xD;
&#xD;
          -  Known or suspected leptomeningeal or brain metastases or spinal cord compression&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
          -  Known impairment of GI function that would alter the absorption&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic treatment within past 2 years&#xD;
&#xD;
          -  History of severe allergic reactions to any of the study intervention components&#xD;
&#xD;
          -  Major surgical procedures within 28 days or non-study-related minor procedures within&#xD;
             7 days of treatment.&#xD;
&#xD;
          -  Prior therapy with KRASG12C inhibitor and/or SHP2 inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Revolution Medicines, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Revolution Medicines, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Revolution Medicines, Inc.</last_name>
    <phone>(650) 779-2300</phone>
    <email>CT-Inquiries@RevMed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GenHarp Clinical Solutions</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charleston Oncology</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHP2</keyword>
  <keyword>NSCLC</keyword>
  <keyword>KRAS G12C</keyword>
  <keyword>BRAF Class 1/2/unclassified</keyword>
  <keyword>KRAS amplification</keyword>
  <keyword>KRAS mutation</keyword>
  <keyword>STK11/LKB1</keyword>
  <keyword>KEAP1</keyword>
  <keyword>PIK3CA</keyword>
  <keyword>ATRX</keyword>
  <keyword>BRCA2</keyword>
  <keyword>carcinoma, non-small lung cancer</keyword>
  <keyword>bronchial neoplasms</keyword>
  <keyword>lung neoplasms</keyword>
  <keyword>respiratory tract neoplasms</keyword>
  <keyword>neoplasms by site</keyword>
  <keyword>neoplasms</keyword>
  <keyword>lung diseases</keyword>
  <keyword>respiratory tract diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

